Back to top
more

Recursion Pharmaceuticals (RXRX)

(Delayed Data from NSDQ)

$3.52 USD

3.52
42,534,847

+0.18 (5.39%)

Updated Jun 26, 2026 04:00 PM ET

After-Market: $3.50 -0.02 (-0.57%) 7:58 PM ET

Zacks Rank:
Message not found:16923

3-Hold of 5     3    

Style Scores:
Message not found:17303

NA Value NA Growth NA Momentum NA VGM

Industry Rank:
Message not found:17304

Bottom 37% (154 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Fundamental Charts

Research for RXRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

About PE Ratio (TTM)

Price to Earnings Ratio or P/E is price x earnings. It is the most commonly used metric for determining a company's value relative to its earnings. In this example, we are using the actual earnings (EPS) for the trailing twelve months (or TTM). A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its trailing twelve months earnings. In general, a lower number or multiple is usually considered better than a higher one.

RXRX 3.52 +0.18(5.39%)

Will RXRX be a Portfolio Killer in June?

Zacks Investment Research is releasing its prediction for RXRX based on the 1-3 month trading system that more than doubles the S&P 500.

Click here - the RXRX analysis is free »

Zacks News for RXRX

Other News for RXRX